Industries > Pharma > Next-Generation Cancer Diagnostics Market Forecast 2017-2027

Next-Generation Cancer Diagnostics Market Forecast 2017-2027

Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques

PUBLISHED: 10 May 2017
PAGES: 166
PRODUCT CODE: PHA0192

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE

The next-generation cancer diagnostics market is expected to grow at a CAGR of 16.5% in the first half of the forecast period and CAGR of 19.1% in the second half of the forecast period. The market is estimated at $1.9bn in 2016 and $4.1bn in 2021.

While the number of new cancer cases is expected to reach 24 million by 2035, the cost savings that could be achieved with early diagnosis will be the main driver for the market. Advances in molecular biology will also help expand the cancer diagnostics test menu.

Companion cancer diagnostics can be costly but we expect them to be increasingly adopted, particularly when choosing expensive cancer therapies. Laboratory automation, standardised commercial cancer tests and affordable benchtop instruments will continue to reduce the costs of molecular testing.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 166-page report you will receive 87 charts – all unavailable elsewhere.

The 166-page report provides clear detailed insight into the next-generation cancer diagnostics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Next-Generation Cancer Diagnostics Market Forecast 2017-2027

Report Scope
Forecasts and analysis of the next-generation cancer diagnostics market from 2017 to 2027.

• 5 next-generation cancer diagnostics submarkets forecast and analysis from 2017 to 2027:
– Advanced PCR Techniques
– In Situ Hybridization (ISH)
– Circulating Tumour Cells (CTCs) Analysis
– Microarray
– Next-Generation Sequencing (NGS)

• Revenue forecasts for 8 leading national or regional next-generation cancer diagnostics market from 2017 to 2027:
– US
– EU5
– Japan
– China
– India
– Brazil
– Russia
– Rest of the World

• Assessment of selected leading companies marketing next-generation cancer diagnostics, examining recent performance and outlooks:
– Roche Diagnostics
– Abbott Laboratories
– Qiagen
– Thermo Fisher Scientific
– Agilent Technologies
– Hologic
– Illumina
– Myriad Genetics

SWOT analysis of the next-generation cancer diagnostics market, and discusses some current trends.

Visiongain’s study is intended for anyone requiring commercial analyses for the next-generation cancer diagnostics market. You find data, trends and predictions.

Buy our report today Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Next-Generation Cancer Diagnostics Market Forecast 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Next-Generation Cancer Diagnostics Market Forecast 2017-2027


Latest Pharma news

Visiongain Publishes Macular Degeneration (AMD) and Other Retinal Diseases Drugs Market Report 2022-2032

The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.

25 November 2022

READ

Visiongain Publishes Top 50 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Report 2022

Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.

25 November 2022

READ

Visiongain Publishes Dermatology CROs Market Report 2022-2032

The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.

23 November 2022

READ

Visiongain Publishes Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.

22 November 2022

READ